If approved, Rytelo could potentially enable patients with low-risk myelodysplastic syndromes to receive treatment for extended periods without needing red blood cell transfusions to relieve symptomatic anemia.
FDA Approves Geron’s Lytero for Treatment of Adults with Low-Risk Myelodysplastic Syndrome
You Might Also Like
Leave a Comment
Latest News
Recent Posts
- Progress of metal cutting technology: Innovative innovation, sustainability, and future labor
- Ceratizit showcases innovation, sustainability and cutting-edge solutions at IMTEX 2025
- Goldman launches an internal GEN AI Assistant with 10K employees
- Taiwan emerges as key player in Indian machine tools market with 20.8% growth
- Automobile companies battle AI bots and recruitment competition